Ipsen appoints Michelle C. Werner as Head of North America
Ipsen has announced the appointment of Michelle C. Werner as Executive Vice President (EVP) and President of North America, effective March 23. She will join the Executive Leadership Team (ELT) and report directly to CEO David Loew.
"She brings extensive experience in leading teams in the U.S. and globally, and possesses a deep understanding of the U.S. market and the significant opportunities it offers Ipsen," commented David Loew.
With a career spanning over 25 years in the pharmaceutical industry, Michelle C. Werner joins the French pharmaceutical company from Alltrna, an American biotech firm where she has served as CEO since 2022.
In her new role at Ipsen, she succeeds Keira Driansky, who is leaving the company to pursue external opportunities following a two-year tenure during which she led a major transformation of the U.S. subsidiary.
David G. Loew is Chief Executive Officer & Director at Ipsen SA and Chief Executive Officer at Ipsen Pharma SAS (a subsidiary of Ipsen SA).
In the past he was Executive Vice President-Sanofi Pasteur at Sanofi and Global Head-Product Strategy at Genentech, Inc.
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (69.2%);
- neuroscience (20.3%);
- rare diseases (10.5%).
At the end of 2025, the group had 7 research and development centers located in France (2), the United Kingdom (2), China (2) and Ireland, and 5 manufacturing sites worldwide.
Net sales are distributed geographically as follows: France (8%), Europe (31.7%), the United States (32.9%), North America (2.2%) and other (25.2%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
